Basel, 2018-10-29 - NBE-Therapeutics was invited to present at Terrapinn's 2018 European Antibody Congress

Ulf Grawunder, CEO of NBE-Therapeutics, was invited to provide an update on NBE-Therapeutics ADC development activities at Terrapinn's European Antibody Congress, which is part of the 2018 Festival of Biologics

Read more

San Francisco, 2018-06-12 - NBE-Therapeutics was invited to present at KNect365's 2018 Next Generation Protein Therapeutics & Bioconjugates Summit

Roger Beerli, CSO of NBE-Therapeutics, was invited to provide an update on NBE-Therapeutics' ADC development activities at KNect365's 2018 Next Generation Protein Therapeutics & Bioconjugates Summit in San Francisco, USA.

Read more

Barcelona, 2018-05-17 - NBE-Therapeutics was invited to present at Vonlanthen's 3rd Annual ADC Summit

Ulf Grawunder, CEO of NBE-Therapeutics, has presented an update on NBE-Therapeutics ADC development activities at at Vonlanthen's 3rd Annual ADC Summit in Barcelona, Spain

Read more

Chicago, 2018-04-14 - NBE-Therapeutics attended the 2018 AACR conference in Chicago

NBE-Therapeutics' CEO Ulf Grawunder presented at this year's AACR conference in Chicago, IL, in mid April

Read more

Berlin, 2018-03-27 - NBE-Therapeutics presented at 2018 World ADC congress

Ulf Grawunder, CEO of NBE-Therapeutics, presented at Hanson-Wade's 8th Annual World-ADC summit-Europe in Berlin at the end of March

Read more

< previous next >